Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB)

Nuvation Bio (NYSE:NUVB)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research report issued on Thursday, MarketBeat reports. They currently have a $5.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 121.73% from the company’s previous close. Wedbush also issued estimates for Nuvation Bio’s Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.05) EPS.

A number of other brokerages have also weighed in on NUVB. JMP Securities began coverage on shares of Nuvation Bio in a research report on Wednesday, April 23rd. They set a “market outperform” rating and a $6.00 target price for the company. Citigroup started coverage on shares of Nuvation Bio in a report on Wednesday, April 23rd. They issued an “outperform” rating for the company. Citizens Jmp initiated coverage on shares of Nuvation Bio in a research note on Wednesday, April 23rd. They issued a “mkt outperform” rating and a $6.00 price objective for the company. Jones Trading initiated coverage on Nuvation Bio in a research report on Wednesday, March 12th. They set a “buy” rating and a $10.00 target price on the stock. Finally, HC Wainwright cut their price target on Nuvation Bio from $11.00 to $10.00 and set a “buy” rating for the company in a report on Monday, March 10th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $7.83.

Nuvation Bio Trading Up 0.7%

Nuvation Bio stock opened at $2.26 on Thursday. Nuvation Bio has a 12 month low of $1.54 and a 12 month high of $3.97. The business’s 50 day simple moving average is $2.00 and its 200 day simple moving average is $2.35. The company has a market cap of $763.72 million, a price-to-earnings ratio of -1.04 and a beta of 1.42.

Nuvation Bio (NYSE:NUVB) last issued its earnings results on Wednesday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $3.08 million during the quarter, compared to the consensus estimate of $0.42 million. As a group, equities research analysts forecast that Nuvation Bio will post -0.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Dongfang Liu sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $2.50, for a total value of $50,000.00. Following the sale, the insider now directly owns 12,000 shares of the company’s stock, valued at $30,000. This trade represents a 62.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO David Hung purchased 200,000 shares of the business’s stock in a transaction on Friday, April 4th. The stock was bought at an average cost of $1.66 per share, with a total value of $332,000.00. Following the purchase, the chief executive officer now owns 58,481,054 shares in the company, valued at approximately $97,078,549.64. This represents a 0.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 29.93% of the company’s stock.

Institutional Investors Weigh In On Nuvation Bio

Hedge funds have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Nuvation Bio in the 4th quarter valued at about $27,000. Forum Financial Management LP bought a new position in shares of Nuvation Bio during the fourth quarter valued at about $29,000. Cerity Partners LLC purchased a new position in Nuvation Bio during the 4th quarter valued at about $31,000. Firethorn Wealth Partners LLC bought a new position in Nuvation Bio during the 1st quarter valued at approximately $35,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Nuvation Bio by 15,183.7% during the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock valued at $42,000 after buying an additional 15,791 shares during the period. 61.67% of the stock is currently owned by institutional investors.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.